Attention Early-Stage Biotech Companies!
Using multi-omic evidence to prioritize therapeutic targets and indications for early-stage biotech companies.
MiraOmics Archive
Articles and Insights
Perspectives on multi-omics, target selection, and technology evaluation.
Attention Pharma and Biotech Contract Research Organizations (CROs)!
Using NGS, multiomics, and spatial analysis to benchmark technologies and support contract research organizations.